查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081921

血友病治療市場：2026-2032年全球市場預測（依血友病類型、藥物類別、給藥途徑、病患年齡層、最終用戶和分銷管道分類）

Hemophilia Treatment Market by Hemophilia Type, Drug Class, Administration Route, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血友病治療市場將成長至 246 億美元，複合年成長率為 6.86%。

主要市場統計數據
基準年 2025 154.5億美元
預計年份：2026年 164.6億美元
預測年份 2032 246億美元
複合年成長率 (%) 6.86%

血友病治療市場簡介

血友病的治療正從控制偶發性出血轉向終身預防、維持關節功能和提高可衡量的生活品質。由VIII因子缺乏引起的A型血友病和由IX因子缺乏引起的B型血友病仍是罕見但影響深遠的遺傳性出血性疾病。經同行評審的盛行率估計表明，每10萬名男性新生兒中約有17.1例A型血友病和3.8例B型血友病。

血友病治療的變革性變化

血友病的治療模式正在經歷結構性轉變，從按需使用因子替代療法轉向以預防性治療為重點的照護模式。由於因子VIII和因子IX製劑的半衰期延長，靜脈輸注的頻率降低。同時，包括基於雙特異性抗體的預防性治療在內的非因子治療方案的擴展，拓寬了預防策略的範圍，尤其適用於存在抑制因子的患者以及希望減輕治療負擔的患者。

人工智慧（AI）的累積影響

人工智慧 (AI) 正日益成為血友病治療整體研發和實施的有力驅動力。 AI 驅動的藥物動力學模型能夠幫助制定個人化的預防性治療方案，預測谷濃度，尤其當與電子輸液記錄、電子健康記錄、實驗室數據以及穿戴式裝置活動數據相結合時，能夠有效減少可避免的出血事件。

區域性血友病治療見解

亞太地區是血友病治療最重要的地區之一。儘管中國和印度的患者數量龐大，但仍存在較高的漏診風險；而日本、澳洲和韓國則擁有成熟的醫療保險報銷體系和先進的預防性療法。北美仍然是全球創新中心，這得益於其專業的血友病治療中心、完善的臨床試驗基礎設施、覆蓋全國的監測體系，以及能夠儘早獲得延長半衰期製劑、非因子預防性療法和基因療法等治療手段。

集團對血友病治療的全面見解

儘管東協市場血友病診斷和治療的覆蓋範圍正在擴大，但新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國的保險報銷體系成熟度存在顯著差異。對於行業供應商而言，在東協市場取得成功取決於分階段的准入模式、醫生培訓、檢測能力的提升以及適應各國公共衛生預算和專科分銷網路的籌資策略。

各國血友病治療情形概覽

美國在臨床創新方面處於領先地位，根據美國疾病管制與預防中心估計，約有33,000名男性患有血友病。另一方面，加拿大受益於其完善的血液疾病診療網路、全面的護理模式和系統的報銷機制。儘管墨西哥的診斷和公共醫療服務取得途徑正在改善，但區域差異仍然存在。巴西憑藉其公共部門採購、國家計畫和專業的醫療保健網路，仍然是拉丁美洲最具影響力的血友病治療中心。

為行業領導者提供的實用建議

產業供應商應優先考慮差異化的證據包，這些證據包應包含年度出血率降低、關節功能數據、抑制劑關聯性、治療負擔、用藥依從性、安全性監測以及患者報告的生活品質 (QOL)。在日益被高成本生物製藥和基因療法主導的市場中，價值證明必須超越臨床試驗終點，涵蓋真實世界的持久性、安全性、治療永續性、醫療資源利用以及長期功能性結果。

調查方法

本執行摘要是基於對公開可用證據的三角檢驗，這些證據來自權威衛生機構、同行評審的流行病學研究、血友病治療指南、法規核准、藥物安全監測資訊以及市場進入模式。主要參考文獻包括世界血友病聯盟 (WFH) 的資源、美國疾病管制與預防中心 (CDC) 的血友病資料、美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 的核准記錄、國家衛生技術評估 (HTA) 結果、臨床指南出版刊物以及已發表的流行病學研究。

結論：血友病治療的未來

血友病治療正進入一個以預防、個人化和持續疾病管理為特徵的新階段。雖然長效凝血因子、非因子預防性療法和基因療法拓寬了臨床選擇，但長期療效取決於安全性監測、對保險公司而言的價值證明、治療機構的容量以及公平的醫療服務取得。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 血友病治療市場：依血友病類型分類

  • A型血友病A
  • B型血友病
  • 血友病C

第8章 血友病治療市場：依藥物類別分類

  • 去氨加壓素
  • 基因治療
  • 重組凝血因子濃縮物
    • 重組因子VIII
    • 重組因子IX
  • 血漿衍生凝血因子濃縮物
  • 非因子替代療法
    • 單株抗體
    • 基於RNA的療法
    • 抗凝血酶抑制劑
  • 抗纖溶藥物

第9章 血友病治療市場：依給藥途徑分類

  • 靜脈
  • 皮下
  • 口服

第10章 血友病治療市場：依患者年齡層別分類

  • 兒童
  • 成人

第11章 血友病治療市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第12章 血友病治療市場：依通路分類

  • 醫院藥房
  • 專科藥房
  • 零售藥房
  • 網路藥房

第13章 血友病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 血友病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血友病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Novo Nordisk A/S
  • Sanofi SA
  • Octapharma AG
  • BioMarin Pharmaceutical Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Alnylam Pharmaceuticals, Inc.
  • Belief BioMed Inc.
  • Biogen Inc.
  • Biotest AG
  • Catalyst Biosciences, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Ferring BV
  • GeneVentiv Therapeutics, Inc.
  • Grifols, SA
  • HEMA Biologics, LLC
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kedrion SpA
  • Medexus Pharma, Inc.
  • Nufactor, Inc.
  • Optum, Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Spur Therapeutics Limited
  • Swedish Orphan Biovitrum AB
  • uniQure NV
Product Code: MRR-4316E4E894CE

The Hemophilia Treatment Market is projected to grow by USD 24.60 billion at a CAGR of 6.86% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.45 billion
Estimated Year [2026] USD 16.46 billion
Forecast Year [2032] USD 24.60 billion
CAGR (%) 6.86%

Hemophilia Treatment Market Introduction

Hemophilia treatment is moving from episodic bleeding control toward lifelong prevention, functional joint preservation, and measurable quality-of-life improvement. Hemophilia A, caused by factor VIII deficiency, and hemophilia B, caused by factor IX deficiency, remain rare but high-impact inherited bleeding disorders; peer-reviewed prevalence estimates place hemophilia A at about 17.1 cases per 100,000 males at birth and hemophilia B at about 3.8 cases per 100,000 males at birth.

For biopharma and treatment innovators, the hemophilia treatment market is defined by recombinant and plasma-derived clotting factors, extended half-life products, non-factor prophylaxis, bypassing agents, immune tolerance approaches for inhibitor management, and gene therapy. Demand is supported by earlier diagnosis, prophylaxis-oriented clinical guidelines, national hemophilia registries, and expanding hemophilia treatment center networks, while adoption is shaped by payer scrutiny, durability data, safety monitoring, and equitable access.

Transformative Shifts in Hemophilia Care

The hemophilia treatment landscape is undergoing a structural shift from on-demand factor replacement to prophylaxis-first care. Extended half-life factor VIII and factor IX therapies have reduced infusion frequency, while non-factor options, including bispecific antibody prophylaxis, have broadened prevention strategies, especially for patients with inhibitors and those seeking lower treatment burden.

Gene therapies for hemophilia A and B have added a potentially transformative, one-time treatment model, but uptake depends on durability of factor expression, liver safety monitoring, patient selection, outcomes-based contracting, and real-world evidence. This creates a market in which product differentiation increasingly depends on clinical convenience, long-term outcomes, adherence, safety profile, and total cost of care rather than factor activity alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across hemophilia treatment development and delivery. AI-supported pharmacokinetic modeling can personalize prophylaxis schedules, predict trough levels, and help reduce avoidable bleeding events, especially when combined with electronic infusion logs, electronic health records, laboratory data, and wearable activity signals.

For manufacturers and care systems, AI can improve clinical trial feasibility by identifying eligible patients, modeling bleeding risk, analyzing real-world evidence, and detecting safety signals earlier. It also supports supply forecasting for high-cost biologics and gene therapies, where inventory planning, cold-chain reliability, treatment center readiness, and patient-specific care pathways are critical to access and commercialization.

Regional Hemophilia Treatment Insights

Asia-Pacific is one of the most important regions for hemophilia treatment because China and India carry large patient populations with substantial underdiagnosis, while Japan, Australia, and South Korea provide mature reimbursement and advanced prophylaxis adoption. North America remains a global innovation hub, supported by specialized hemophilia treatment centers, strong clinical trial infrastructure, national surveillance activity, and early access to extended half-life products, non-factor prophylaxis, and gene therapy.

Latin America shows improving access through public procurement and national programs, with Brazil and Mexico playing central roles, but budget variability and unequal specialist access continue to affect treatment consistency. Europe combines high clinical standards with cost-sensitive reimbursement, health technology assessment, national tender systems, and strong registry activity that influence product positioning across EU and non-EU markets.

The Middle East, led by GCC health systems, is investing in specialty care, genetic counseling, advanced biologics, and digital health infrastructure, while broader access varies by national financing capacity. Africa has the largest unmet need relative to diagnosis and treatment availability; WFH-supported training, humanitarian aid, basic laboratory capacity, and registry development remain essential for moving care from acute bleeding management toward prophylaxis and long-term joint protection.

Group-Level Hemophilia Treatment Insights

ASEAN markets are expanding hemophilia diagnosis and access, but reimbursement maturity differs sharply between Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. For industry vendors, ASEAN success depends on tiered access models, physician education, laboratory strengthening, and procurement strategies that fit diverse public health budgets and specialist distribution.

The GCC is positioned for faster adoption of high-value hemophilia therapies because centralized purchasing, specialist hospitals, genetic counseling programs, and digital health investment can support complex biologic and gene therapy pathways. The European Union is shaped by centralized regulatory science, national reimbursement decisions, cross-border clinical expertise, and the growing influence of EU-level health technology assessment, making comparative evidence, safety monitoring, and patient-reported outcomes essential.

BRICS countries represent scale: Brazil, Russia, India, China, and South Africa combine large patient pools with growing domestic manufacturing ambitions and persistent access gaps. G7 markets drive premium innovation, evidence standards, pharmacovigilance expectations, and early adoption of advanced therapies. NATO countries, many of which overlap with high-income European and North American systems, increasingly emphasize medicine security, resilient supply chains, emergency preparedness, and continuity of care for rare disease patients.

Country-Level Hemophilia Treatment Insights

The United States leads in clinical innovation, with the CDC estimating that as many as 33,000 males live with hemophilia, while Canada benefits from coordinated blood disorder networks, comprehensive care models, and structured reimbursement. Mexico is improving diagnosis and public access, though regional disparities persist, and Brazil remains Latin America's most influential hemophilia treatment environment due to public-sector purchasing, national programs, and specialist care networks.

The United Kingdom, Germany, France, Italy, and Spain maintain advanced hemophilia treatment systems with strong specialist centers, guideline-based prophylaxis, and established reimbursement pathways, but payer assessment and budget impact guide uptake of premium therapies. Russia has a sizable diagnosed population and centralized procurement dynamics, although access conditions can vary by region and policy environment.

China is expanding treatment capacity through reimbursement reforms, hospital network development, and domestic biologic competition, while India faces a high underdiagnosed burden and needs stronger registry, affordability, factor availability, and prophylaxis infrastructure. Japan, Australia, and South Korea are mature Asia-Pacific markets with high clinical standards, advanced reimbursement, established hemophilia care expertise, and growing interest in therapies that reduce infusion burden and improve long-term joint health.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize differentiated evidence packages that combine annualized bleeding rate reduction, joint outcome data, inhibitor relevance, treatment burden, adherence, safety monitoring, and patient-reported quality of life. In a market increasingly shaped by high-cost biologics and gene therapy, value demonstration must extend beyond trial endpoints to real-world durability, safety, persistence, healthcare resource utilization, and long-term functional outcomes.

Commercial strategy should include early payer dialogue, outcomes-based agreements where appropriate, patient identification partnerships, treatment center readiness, and registry-enabled post-marketing evidence. Manufacturers should also invest in clinician and patient education for shared decision-making, because stakeholders must compare prophylaxis convenience, breakthrough bleed protection, gene therapy eligibility, monitoring requirements, reversibility considerations, and long-term uncertainty.

Research Methodology

This executive summary is based on triangulation of publicly available evidence from recognized health authorities, peer-reviewed epidemiology, hemophilia treatment guidelines, regulatory approvals, pharmacovigilance information, and market access patterns. Key reference categories include WFH resources, CDC hemophilia data, FDA and EMA approval records, national health technology assessment outputs, clinical guideline publications, and published prevalence studies.

Insights were validated through cross-comparison of disease burden, treatment adoption, reimbursement structures, clinical innovation, safety considerations, registry evidence, and regional access indicators. The analysis avoids speculative claims and emphasizes evidence-backed trends that are relevant to hemophilia treatment manufacturers, providers, payers, patient organizations, and policy stakeholders.

Conclusion: Future of Hemophilia Treatment

Hemophilia treatment is entering a new phase defined by prevention, personalization, and durable disease control. Extended half-life factors, non-factor prophylaxis, and gene therapy have expanded the clinical toolkit, but long-term success will depend on safety monitoring, payer-aligned value evidence, treatment center capability, and equitable access.

The next competitive advantage will come from integrating clinical innovation with real-world evidence, AI-enabled care optimization, and region-specific access strategies. Organizations that align product performance with patient outcomes, healthcare system affordability, and reliable supply continuity will be best positioned in the evolving hemophilia treatment market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hemophilia Treatment Market, by Hemophilia Type

  • 7.1. Hemophilia A
  • 7.2. Hemophilia B
  • 7.3. Hemophilia C

8. Hemophilia Treatment Market, by Drug Class

  • 8.1. Desmopressin
  • 8.2. Gene Therapies
  • 8.3. Recombinant Coagulation Factor Concentrates
    • 8.3.1. Recombinant Factor VIII
    • 8.3.2. Recombinant Factor IX
  • 8.4. Plasma-Derived Coagulation Factor Concentrates
  • 8.5. Non-Factor Replacement Therapies
    • 8.5.1. Monoclonal Antibodies
    • 8.5.2. RNA-based Therapies
    • 8.5.3. Antithrombin Inhibitors
  • 8.6. Antifibrinolytic Agents

9. Hemophilia Treatment Market, by Administration Route

  • 9.1. Intravenous
  • 9.2. Subcutaneous
  • 9.3. Oral

10. Hemophilia Treatment Market, by Patient Age Group

  • 10.1. Pediatric
  • 10.2. Adult

11. Hemophilia Treatment Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Specialized Clinics

12. Hemophilia Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Specialty Pharmacies
  • 12.3. Retail Pharmacies
  • 12.4. Online Pharmacies

13. Hemophilia Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Hemophilia Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hemophilia Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Takeda Pharmaceutical Company Limited
  • 17.2. CSL Limited
  • 17.3. F. Hoffmann-La Roche Ltd.
  • 17.4. Bayer AG
  • 17.5. Novo Nordisk A/S
  • 17.6. Sanofi S.A.
  • 17.7. Octapharma AG
  • 17.8. BioMarin Pharmaceutical Inc.
  • 17.9. Shanghai RAAS Blood Products Co., Ltd.
  • 17.10. Alnylam Pharmaceuticals, Inc.
  • 17.11. Belief BioMed Inc.
  • 17.12. Biogen Inc.
  • 17.13. Biotest AG
  • 17.14. Catalyst Biosciences, Inc.
  • 17.15. Chugai Pharmaceutical Co., Ltd.
  • 17.16. Ferring B.V.
  • 17.17. GeneVentiv Therapeutics, Inc.
  • 17.18. Grifols, S.A.
  • 17.19. HEMA Biologics, LLC
  • 17.20. Hualan Biological Engineering Inc.
  • 17.21. Intas Pharmaceuticals Ltd.
  • 17.22. Kedrion S.p.A.
  • 17.23. Medexus Pharma, Inc.
  • 17.24. Nufactor, Inc.
  • 17.25. Optum, Inc.
  • 17.26. Pfizer Inc.
  • 17.27. Sangamo Therapeutics, Inc.
  • 17.28. Spur Therapeutics Limited
  • 17.29. Swedish Orphan Biovitrum AB
  • 17.30. uniQure N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMOPHILIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEMOPHILIA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMOPHILIA A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMOPHILIA A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMOPHILIA A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEMOPHILIA B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMOPHILIA B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEMOPHILIA B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMOPHILIA C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMOPHILIA C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMOPHILIA C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DESMOPRESSIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DESMOPRESSIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT FACTOR VIII MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT FACTOR VIII MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT FACTOR VIII MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT FACTOR IX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT FACTOR IX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT FACTOR IX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-FACTOR REPLACEMENT THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-FACTOR REPLACEMENT THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-FACTOR REPLACEMENT THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA-BASED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA-BASED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTITHROMBIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTITHROMBIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTITHROMBIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIFIBRINOLYTIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIFIBRINOLYTIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIFIBRINOLYTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 155. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. G7 HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 182. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. NATO HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 191. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 192. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY NON-FACTOR REPLACEMENT THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)